This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Zuprata

Clearside Biomedical, Inc.

Drug Names(s): CLS-TA with intravitreal injection of anti-VEGF compound, CLS-1003, CLS1003, CLS 1003

Description: CLS-1003 consists of an SCS injection of CLS-TA, Clearside's proprietary formulation of triamcinolone acetonide, with the company's microinjector, for administration together with an intravitreal injection of an anti-VEGF drug.


Zuprata News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug